Log In | Register
0 Comments
Printadvertisement
WASHINGTON — Biotech drugmaker Biogen Idec said Friday it has extended its tender offer for shares of Facet Biotech Corp., after the company's board unanimously rejected the hostile takeover bid.
On Sept. 21, Biogen launched an unsolicited tender offer of $14.50 per share for Facet stock. That offer would have expired Oct. 19, though Biogen said it will be extended until Dec. 16.
"We continue to believe our offer reflects a full and fair price and provides Facet Biotech stockholders the opportunity to realize the value today of Facet's development stage pipeline," said Biotech Chief Executive James Mullen, in a statement.
Since 2005, the companies have been collaborating to develop the cancer drug candidate volociximab and the multiple sclerosis drug daclizumab.
Cambridge, Mass.-based Biogen went public with the bid on Sept. 4. Facet rejected it Sept. 8, saying it undervalued the company.
Shares of Facet Biotech Corp. rose 11 cents Friday to close at $18.03.
© 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
0 Votes- Enjoy this article? Help vote it up the 'Vine.
Published to:
- Associated Press's Column, All of Newsvine
- Groups: none
- Regions: Washington DC
- Public Discussion (0)
{"canLink":false,"threadId":0,"isPrivate":false}
You're in Easy Mode. If you prefer, you can use XHTML Mode instead. |
As a new user, you may notice a few temporary content restrictions. Click here for more info.
Start Tracking
Stop TrackingCOMPANY STUFF:
LEGAL STUFF:
- © 2005-2010 Newsvine, Inc. |
- Newsvine® is a registered trademark of Newsvine, Inc. |
- Newsvine is a property of
